J. Goldman & Co’s Pfizer PFE Stock Holding History

J. Goldman & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,856	Closed	-$614K	–	875
2026 Q1	$614K	Buy	+21,856	New	+$582K	0.02%	482
2025 Q2	–	Sell	-177,251	Closed	-$4.49M	–	598
2025 Q1	$4.49M	Sell	177,251 -133,872	-43%	-$3.5M	0.11%	221
2024 Q4	$8.25M	Buy	+311,123	New	+$8.44M	0.22%	143
2023 Q4	–	Sell	-58,429	Closed	-$1.77M	–	439
2023 Q3	$1.94M	Buy	+58,429	New	+$2.07M	0.07%	205
2022 Q1	–	Sell	-128,713	Closed	-$7.6M	–	422
2021 Q4	$7.6M	Buy	+128,713	New	+$6.38M	0.42%	66
2020 Q4	–	Sell	-33,553	Closed	-$1.17M	–	460
2020 Q3	$1.17M	Buy	+33,553	New	+$1.18M	0.08%	205
2015 Q4	–	Sell	-236,017	Closed	-$7.03M	–	286
2015 Q3	$7.03M	Buy	+236,017	New	+$7.57M	0.6%	50
2014 Q4	–	Sell	-157,501	Closed	-$4.42M	–	257
2014 Q3	$4.42M	Buy	157,501 +9,099	+6%	+$255K	0.27%	112
2014 Q2	$4.18M	Buy	148,402 +64,374	+77%	+$1.84M	0.31%	93
2014 Q1	$2.56M	Buy	+84,028	New	+$2.51M	0.19%	152
2013 Q3	–	Sell	-71,356	Closed	-$1.9M	–	305
2013 Q2	$1.9M	Buy	+71,356	New	+$1.97M	0.19%	142

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

J. Goldman & Co's PFE Position: Q2 2026 in Review

J. Goldman & Co sold out of Pfizer (PFE) in Q2 2026, closing a stake of 21,856 shares — an estimated $614K sold.

J. Goldman & Co first reported a position in PFE in Q2 2013 and held it in 11 quarters. The position peaked at $8.25M in Q4 2024. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

J. Goldman & Co reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 21,856 Pfizer shares in Q2 2026, an estimated $614K.
J. Goldman & Co first reported a position in Pfizer in Q2 2013 and held it in 11 quarters.
J. Goldman & Co's Pfizer position peaked at $8.25M in Q4 2024.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.